05.12.2022 Fresenius SE & Co. KGaA  DE0005785604

EQS-Adhoc: Helen Giza is the new CEO of Fresenius Medical Care; Dr. Carla Kriwet leaves the company


 

EQS-Ad-hoc: Fresenius SE & Co. KGaA / Key word(s): Personnel
Helen Giza is the new CEO of Fresenius Medical Care; Dr. Carla Kriwet leaves the company

05-Dec-2022 / 23:40 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Helen Giza is the new CEO of Fresenius Medical Care; Dr. Carla Kriwet leaves the company

Today, the Supervisory Board of Fresenius Medical Care Management AG, the General Partner of Fresenius Medical Care AG & Co. KGaA, has unanimously appointed Helen Giza as CEO of the Management Board with effect as of 6 December 2022. Helen Giza continues to serve as Chief Financial Officer of Fresenius Medical Care until further notice. Her predecessor, Dr. Carla Kriwet is leaving the company at her own request and by mutual agreement due to strategic differences.

As CEO of Fresenius Medical Care, Helen Giza will also join the Management Board of Fresenius Management SE. Dr. Carla Kriwet will leave the Management Board of Fresenius Management SE.

Fresenius SE & Co. KGaA, 
represented by Fresenius Management SE, 
The Management Board

Bad Homburg v.d.H., December 5, 2022

----------------------------------------
Contact:
Markus Georgi
Senior Vice President Investor Relations & Sustainability
T: +49 (0) 6172 608-2485
[email protected]
----------------------------------------

End of Note
 

05-Dec-2022 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Fresenius SE & Co. KGaA
Else-Kröner-Straße 1
61352 Bad Homburg v.d.H.
Germany
Phone: +49 (0)6172 608-2485
Fax: +49 (0)6172 608-2488
E-mail: [email protected]
Internet: www.fresenius.com
ISIN: DE0005785604
WKN: 578560
Indices: DAX
Listed: Regulated Market in Dusseldorf, Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Hamburg, Hanover, Stuttgart, Tradegate Exchange; Luxembourg Stock Exchange
EQS News ID: 1505587

 
End of Announcement EQS News Service

1505587  05-Dec-2022 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1505587&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023
Umsatzerlöse1 33.530,00 35.409,00 37.250,00 36.277,00 37.520,00 40.840,00 22.299,00
EBITDA1,2 6.267,00 6.032,00 7.083,00 7.132,00 6.854,00 6.808,00 3.422,00
EBITDA-Marge3 18,69 17,04 19,01 19,66 18,27 16,67
EBIT1,4 4.589,00 5.251,00 4.631,00 4.385,00 4.158,00 3.321,00 1.143,00
EBIT-Marge5 13,69 14,83 12,43 12,09 11,08 8,13 5,13
Jahresüberschuss1 1.816,00 1.871,00 1.915,00 2.823,00 2.819,00 2.117,00 -594,00
Netto-Marge6 5,42 5,28 5,14 7,78 7,51 5,18 -2,66
Cashflow1,7 3.937,00 3.742,00 4.263,00 6.549,00 5.078,00 4.198,00 4.456,00
Ergebnis je Aktie8 3,25 3,37 3,44 3,06 3,26 2,44 -1,05
Dividende8 0,75 0,80 0,84 0,88 0,92 0,92 0,62
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: PricewaterhouseCoopers

INVESTOR-INFORMATIONEN
©boersengefluester.de
Fresenius
WKN Kurs in € Einschätzung Börsenwert in Mio. €
578560 29,960 Halten 16.874,59
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
14,40 16,78 0,86 12,06
KBV KCV KUV EV/EBITDA
0,89 3,79 0,76 8,81
Dividende '22 in € Dividende '23 in € Div.-Rendite '23
in %
Hauptversammlung
0,92 0,00 0,00 17.05.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
08.05.2024 31.07.2024 06.11.2024 20.03.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
4,11% 10,34% 6,73% 5,23%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Fresenius SE & Co. KGaA  ISIN: DE0005785604 können Sie bei EQS abrufen


Medtech , 578560 , FRE , XETR:FRE